Navigation Links
Triglyceride Levels Continue to Rise in the United States Despite Increased Use of Cholesterol-Lowering Medications
Date:11/11/2008

the development of heart related issues. Diagnosis of these abnormal cholesterol levels is commonly determined by blood levels of total cholesterol, triglycerides, high density lipoprotein (HDL) cholesterol and low density lipoprotein (LDL) cholesterol.

HealthCore, a subsidiary of WellPoint, is a health outcomes and clinical research organization that has served the needs of health plans, government agencies, physician practices and pharmaceutical manufacturers since 1996. HealthCore focuses on providing evidence of the real-world safety and effectiveness of therapeutics; offering insight to best utilize this evidence; and communicating these findings to health care decision-makers. The company's work is increasingly used to support evidence-based medicine, process improvement and patient-reported outcomes.

This study was conducted by the National Lipid Association Consumer Affairs Committee, with the support of an independent grant from Abbott Laboratories.

About WellPoint, Inc.

WellPoint, Inc. is the largest publicly traded commercial health benefits company in terms of membership in the United States. WellPoint, Inc. is an independent licensee of the Blue Cross Blue Shield Association and serves its members as the Blue Cross licensee for California; the Blue Cross and Blue Shield licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (as Blue Cross Blue Shield in 10 New York City metropolitan counties and as Blue Cross, Blue Shield or Blue Cross Blue Shield in selected upstate counties only), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.), Wisconsin; and through UniCare. Additional information about WellPoint is available at http://www.wellpoint.com .

About the National Lipid Association

The National Lipid Association (NLA) is a multidi
'/>"/>

SOURCE WellPoint, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
2. Abbotts Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study
3. High triglycerides, other cholesterol raise risk of stroke
4. High Blood Triglycerides Linked to Stroke Risk
5. Tackling Triglycerides: 8 Ways to Solve a Big Fat Problem, From the Harvard Heart Letter
6. Triglycerides Linked to Coronary Disease Risk
7. Pittsburgh scientists find protein may be key to new therapies for elevated triglycerides
8. Adult offspring of parents with PTSD have lower cortisol levels
9. Screening Proposed for Childhood Cholesterol Levels
10. Womens Folic Acid Levels Improving
11. Giving emergency nurses aromatherapy massages with music dramatically reduced stress levels
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Health Care Without Harm Applauds EPA Finding Climate Change is Danger to Public Health 2Health News:Health Care Without Harm Applauds EPA Finding Climate Change is Danger to Public Health 3Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 2Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 3Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 4Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 5Health News:U.S. Cancer Cases, Deaths Continue to Drop 2Health News:U.S. Cancer Cases, Deaths Continue to Drop 3Health News:U.S. Cancer Cases, Deaths Continue to Drop 4Health News:New approach to sickle-cell disease shows promise in mice 2Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 2Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 3Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 4Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 5
Breaking Medicine Technology:Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 2Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 3Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 4Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 5New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3European Lung Cancer Screening Trial Demonstrates New Inexpensive Strategy for Improving Accuracy of Diagnosis 2Study to Investigate AHCC and the Swine Flu Virus 47555 1Study to Investigate AHCC and the Swine Flu Virus 47555 2Consumer Reports 3A Hearing Aid Shoppers Pay High Prices Get Mediocre Fittings 47551 1Consumer Reports 3A Hearing Aid Shoppers Pay High Prices Get Mediocre Fittings 47551 2Consumer Reports 3A Hearing Aid Shoppers Pay High Prices Get Mediocre Fittings 47551 3Consumer Reports 3A Hearing Aid Shoppers Pay High Prices Get Mediocre Fittings 47551 4PROTECT 1 Phase II III Induction Stage Results for ChemoCentryxs Traficet EN 28TM 29 Presented in Oral Session at DDW 2009 Conference 4508 1PROTECT 1 Phase II III Induction Stage Results for ChemoCentryxs Traficet EN 28TM 29 Presented in Oral Session at DDW 2009 Conference 4508 2PROTECT 1 Phase II III Induction Stage Results for ChemoCentryxs Traficet EN 28TM 29 Presented in Oral Session at DDW 2009 Conference 4508 3PROTECT 1 Phase II III Induction Stage Results for ChemoCentryxs Traficet EN 28TM 29 Presented in Oral Session at DDW 2009 Conference 4508 4PROTECT 1 Phase II III Induction Stage Results for ChemoCentryxs Traficet EN 28TM 29 Presented in Oral Session at DDW 2009 Conference 4508 5PROTECT 1 Phase II III Induction Stage Results for ChemoCentryxs Traficet EN 28TM 29 Presented in Oral Session at DDW 2009 Conference 4508 6